Adagio Therapeutics Statistics Share Statistics Adagio Therapeutics has 108.98M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 108.98M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 53.51M Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 4.65M, so 0% of the outstanding
shares have been sold short.
Short Interest 4.65M Short % of Shares Out n/a Short % of Float 12.82% Short Ratio (days to cover) 5.1
Valuation Ratios The PE ratio is -3.56 and the forward
PE ratio is null.
Adagio Therapeutics's PEG ratio is
0.
PE Ratio -3.56 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 1.45 P/FCF Ratio -4.37 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Adagio Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 9.94,
with a Debt / Equity ratio of 0.
Current Ratio 9.94 Quick Ratio 9.94 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-2.25M Employee Count 101 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 118K Effective Tax Rate -0.05%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Adagio Therapeutics's
price volatility has been lower than the market average.
Beta 0 52-Week Price Change n/a 50-Day Moving Average 4.12 200-Day Moving Average n/a Relative Strength Index (RSI) 58.5 Average Volume (20 Days) n/a
Income Statement
Revenue n/a Gross Profit n/a Operating Income -226.79M Net Income -226.79M EBITDA -225.36M EBIT -226.79M Earnings Per Share (EPS) -2.04
Full Income Statement Balance Sheet The company has 542.22M in cash and 0 in
debt, giving a net cash position of 542.22M.
Cash & Cash Equivalents 542.22M Total Debt n/a Net Cash n/a Retained Earnings -292.11M Total Assets 484.61M Working Capital 413.48M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -184.74M
and capital expenditures -84K, giving a free cash flow of -184.82M.
Operating Cash Flow -184.74M Capital Expenditures -84K Free Cash Flow -184.82M FCF Per Share -1.66
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
